Biogen reported Phase 2 efficacy in lupus with litifilimab, its anti-BDCA2 antibody being positioned as a pillar of its immunology pipeline. In the company’s program update for skin involvement, litifilimab improved cutaneous lesions at 24 weeks, with 14.7% of patients reaching the reported response threshold. The update comes as BDCA2 targeting remains a competitive immunology strategy, with continued scrutiny on durability of skin benefit and downstream impacts across systemic manifestations. Biogen’s next steps include clarifying how these findings will support broader development decisions. Investors and competitors will focus on whether the skin signal translates into higher-value endpoints and whether the program can differentiate from existing interferon-pathway approaches in lupus.